Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3117-3123

  Kreth, F W ^a   Thon, N ^a   Simon, M ^b   Westphal, M ^c   Schackert, G ^d   Nikkhah, G ^e   Hentschel, B ^f   Reifenberger, G ^g   Pietsch, T ^b   Weller, M ^h   Tonn, Joerg Christian ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Biopsy; Extent of resection; Glioblastoma; MGMT; Prognosis; Temozolomide

Indexed keywords

BEVACIZUMAB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; TEMOZOLOMIDE;

ADULT; AGE; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; GIANT CELL GLIOBLASTOMA; GLIOBLASTOMA; GLIOSARCOMA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METHYLATION; MORBIDITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY;

BIOPSY; EXTENT OF RESECTION; GLIOBLASTOMA; MGMT; PROGNOSIS; TEMOZOLOMIDE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888784235     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt388     Document Type: Article

References (22)

1. Louis D, Ohgaki H, Wiestler O et al. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC Press, 2007.
2. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Hegi ME, Diserens AC, Gorlia T et al. MGMT Gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
4. Felsberg J, Rapp M, Loeser S et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009; 15: 6683-6693.
5. Senft C, Bink A, Franz K et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011; 12: 997-1003.
6. Stummer W, Reulen HJ, Meinel T et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62: 564-576.
7. Gulati S, Jakola AS, Nerland US et al. The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg 2011; 76: 572-579.
8. Jakola AS, Gulati S, Weber C et al. Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study. PLoS One 2011; 6: e28592.
9. Thon N, Eigenbrod S, Grasbon-Frodl EM et al. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. J Neurol Neurosurg Psychiatry 2011; 82: 441-446.
10. Stummer W, Pichlmeier U, Meinel T et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.
11. Macdonald DR, Cascino TL, Schold SC, Jr et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
12. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
13. Orringer D, Lau D, Khatri S et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg 2012; 117: 851-859.
14. Chinot O, Wick W, Mason W et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAGlio. Neurooncology 2012; 14: vi101-vi105.
15. Stummer W, Tonn JC, Mehdorn HM et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg 2011; 114: 613-623.
16. Laws ER, Parney IF, Huang W et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003; 99: 467-473.
17. Gorlia T, van den Bent MJ, Hegi ME et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008; 9: 29-38.
18. Barker FG, Chang SM. Improving resection of malignant glioma. Lancet Oncol 2006; 7: 359-360.
19. Sanai N, Polley MY, McDermott MW et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011; 115: 3-8.
20. Kubben PL, ter Meulen KJ, Schijns OE et al. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol 2011; 12: 1062-1070.
21. Kubben PL, Postma AA, Kessels AG et al. Intraobserver and interobserver agreement in volumetric assessment of glioblastoma multiforme resection. Neurosurgery 2010; 67: 1329-1334.
22. Kreth FW, Berlis A, Spiropoulou V et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 1999; 86: 2117-2123.